Lannett Launches Aspirin And Extended-Release Dipyridamole Capsules
PHILADELPHIA, June 18, 2019 -- (Healthcare Sales & Marketing Network) -- Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, the therapeutic equivalent to the ... Biopharmaceuticals, Generics Lannett Company, Aggrenox, Dipyridamole, Boehringer Ingelheim (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 18, 2019 Category: Pharmaceuticals Source Type: news
Lannett Receives FDA Approval For Aspirin And Extended-Release Dipyridamole Capsules, 25 mg/200 mg
PHILADELPHIA, March 27, 2019 -- (Healthcare Sales & Marketing Network) -- Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Aspir... Biopharmaceuticals, Generics, FDA Lannett Company, Boehringer Ingelheim, Aggrenox (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 27, 2019 Category: Pharmaceuticals Source Type: news
Dr Reddy's launches anti-coagulant drug in US market
Dr Reddy's Aspirin and extended-release Dipyridamole capsules is available in 25 mg/200 mg strength with 60 count bottle size. Aggrenox is a trademark of Boehringer lngelheim. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 24, 2018 Category: Pharmaceuticals Source Type: news
Aggrenox (Aspirin, Extended-Release Dipyridamole Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 27, 2018 Category: Drugs & Pharmacology Source Type: news
